Back to search

Boston University

Interrogating the Hippo/YAP signaling pathway to preserve fertility in cancer survivors

Abstract

dc:description.abstract

The advancement in cancer treatments has led to significantly improved survival rates, but fertility, an essential component of the life quality of cancer survivors, deteriorated or was even damaged. There are over 1.27 million cancer survivors in the U.S., and over 51% of women are concerned about becoming infertile upon cancer treatment. Fertility preservation for cancer survivors becomes an evident priority for researchers and clinicians globally. The objective of this study was to understand the relationship between Hippo/YAP signaling and fertility in the context of cancer. This was accomplished through cell culture studies, immunohistochemical staining (IHC), immunofluorescence (IF), and DNA fragmentation assays (TUNEL) to assess the impact of chemotherapy on follicle health and to investigate the role of YAP in this process. Mice were injected with chemotherapy drugs (Cisplatin and Paclitaxel), TRULI (LATS 1/2 inhibitor), and a combination of the two drugs at different dosages. The ovaries were isolated, fixed, sectioned, and stained for IHC and IF. Cell culture studies revealed the timely expression of YAP1 as a critical regulator for granulosa cell development and possible treatment regimens using TRULI. Staining of γH2AX, Ser-139 phosphorylated form of the minor histone H2A variant, showed a positive signal for primordial and primary follicles with granulosa cell involvement in the chemotherapy groups, indicating possible DNA damage for early-stage ovarian follicles. Additionally, the TUNEL assay was conducted on a granulosa cell culture to confirm DNA fragmentation across various experimental groups, and these values were taken as ratios of TUNEL-positive cells divided by the total number of nuclei. The results showed an 11.6% TUNEL-positive value in the group treated with chemotherapy. In contrast, the control group with growth medium only had a 3.2% TUNEL positive value. The TRULI-only group had a 6.2% TUNEL-positive value, and the TRULI + Chemotherapy group had an 8.8% TUNEL-positive assay value. This confirmed that chemotherapy groups induce more damage to granulosa cells surrounding the oocyte compared to other groups. KGN morphology changes revealed that low-dose TRULI (2.5 uM) was optimal for cell growth. Protective and recovery treatment regimens for TRULI administration illustrated normal morphology and active growth. Finally, corpus luteum numbers were counted across various treatment conditions, and we concluded that there were fewer corpus luteum in the chemotherapy group when compared to the control, indicating some ovarian dysfunction due to treatment. We were able to conclude that chemotherapy induces damage to follicles and TRULI, a LATS 1/2 inhibitor, is a good potential therapeutic for this issue that shows promising results.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Medical Sciences
Grantor
Boston University
Year dc:date.issued
2025

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Polakkattil, Aneeta
Advisors dc:contributor.advisor
  • Mellott, Tiffany
  • Wang, Cheng
ORCID dc:identifier.orcid

Subjects

dc:subject × 7

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/52354

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Polakkattil, Aneeta. Interrogating the Hippo/YAP signaling pathway to preserve fertility in cancer survivors. masters thesis, Boston University, 2025. https://hdl.handle.net/2144/52354